TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9877147
Drug: AT4 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT4 (4 mmol x l(‐1) threshold)
Study: 8560416
Drug: DDAVP (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.3 microgram/kg intravenous infusion)
Study: 8560416
Drug: DDAVP (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.3 microgram/kg intravenous infusion) in Group I patients
Study: 8560416
Drug: DDAVP (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.3 microgram/kg intravenous infusion) in Group II patients
Study: 8560416
Drug: DDAVP (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.3 microgram/kg intravenous infusion) in Group III patients
Study: 81125
Drug: Gamma-globulin intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-globulin intramuscularly administered 24 hours after infection
Study: 31862312
Drug: Single supra-therapeutic
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single supra-therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 400/24/50 µg)
Study: 31862312
Drug: Therapeutic inhaled
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 200/12/25 µg), twice daily for 7 consecutive days
Study: 30690191
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with oral placebo (Group A)
Study: 30690191
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with oral metformin (Group B)
Study: 12968235
Drug: GIK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK therapy
Study: 21303634
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus insulin injections once an hour
Study: 16448552
Drug: Sulfasalazine (1.5-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (1.5-6 g daily, orally t.i.d.)
Study: 15303786
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent with occlusion (bioceramic-coated neoprene garment)
Study: 15303786
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent without occlusion
Study: 9257414
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin D3 administration
Study: 8218671
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg orally every 12 hours
Study: 3497990
Drug: PRP-D vaccine
Normalized name: Hib (PRP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D vaccine (two doses, separated by two months)
Study: 20569170
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment with adjunctive dose of vitamin C (ChP1)
Study: 20569170
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment alone (ChP2)
Study: 20569170
Drug: Adjunctive vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive vitamin C
Study: 17711908
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclophosphamide (CYC), calcineurine inhibitors (cyclosporine or tacrolimus), mycophenolate mofetil, azathioprine, rituximab
Study: 17711908
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment regimens including high doses of cyclophosphamide (CYC) and steroids
Study: 26708320
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg/day
Study: 11379805
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 60 mg/day
Study: 9225837
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (2 IU/m2) for 12 months
Study: 3301500
Drug: Verapamil (V)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (V) 240 mg/die
Study: 3301500
Drug: Chlorthalidone (C)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (C) 50 mg/die
Study: 3301500
Drug: Verapamil (V)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (V) 240 mg/die + Chlorthalidone (C) 50 mg/die (V + C)
Study: 28851063
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT, n = 10)
Study: 20858400
Drug: bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: bimatoprost/timolol fixed combination
Study: 12562448
Drug: Lansoprazole orally
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole orally disintegrating tablet, 15 mg
Study: 12562448
Drug: Lansoprazole orally
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole orally disintegrating tablet, 30 mg
Study: 12562448
Drug: Intact capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact capsule formulation of lansoprazole
Study: 8637408
Drug: Velnacrine (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine (30, 75, 150, 225 mg/day for one week)
Study: 1350927
Drug: Acetorphan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (100 mg t.d.s.)
Study: 6529914
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Ro 21-5521 per day
Study: 30904178
Drug: Telmisartan/Amlodipine 80/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine 80/10 mg + Rosuvastatin 20 mg (TAR group)
Study: 30904178
Drug: Telmisartan/Amlodipine 80/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine 80/10 mg (TA group)
Study: 30904178
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + Rosuvastatin 20 mg (TR group)
Study: 24184810
Drug: Simeprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks
Study: 24184810
Drug: Simeprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (100 or 150 mg, once daily)
Study: 22266898
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL mepivacaine 1.5%
Study: 22266898
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL mepivacaine 1.5%
Study: 10901509
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (0.625 mg conjugated oestrogen and 2.5 mg medroxyprogesterone acetate daily)
Study: 10901509
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (simvastatin + hormone replacement therapy)
Study: 8622055
Drug: Alternating regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating regimen (one cycle of MOPP monthly alternated with one cycle of ABVD)
Study: 6367362
Drug: Sulpiride (800-2800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (800-2800 mg/day, median 1600 mg/day)
Study: 6367362
Drug: Haloperidol (6-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (6-18 mg/day, median 12 mg/day)
Study: 31465088
Drug: mFOLFOX6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 plus aflibercept (4 mg/kg every 2 weeks for 6 cycles, 3 months)
Study: 23122916
Drug: VNS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VNS therapy (all doses)
Study: 8783326
Drug: Intra-articular clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular clonidine 150 micrograms diluted in 20 ml of isotonic saline
Study: 8783326
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg diluted in 20 ml of isotonic saline injected into the knee joint
Study: 8783326
Drug: Intra-articular isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular isotonic saline and subcutaneous clonidine 150 micrograms
Study: 1740587
Drug: Phenylephrine (alpha-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (alpha-adrenergic agonist)
Study: 1740587
Drug: Beta-adrenergic agonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic agonists
Study: 27127102
Drug: Valsartan/Amlodipine (Val/Aml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine (Val/Aml 80/5 mg) single-pill combination for 8 weeks
Study: 23532242
Drug: Erythromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (400 mg, twice daily)
Study: 20399059
Drug: Niacin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (target dose, 2000 mg/day)
Study: 19932541
Drug: Lovastatin, 20
Normalized name: Lovastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin, 20 mg/d
Study: 10447643
Drug: Lomefloxacin 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 0.3% eye drops twice daily (LF)
Study: 10447643
Drug: Control antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control antibiotics (combined control group, CCG)
Study: 8681494
Drug: Quinaprilat (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaprilat (0.5 to 1.0 mg, 1.0 to 2.5 mg, 5.0 to 10.0 mg)
Study: 8681494
Drug: Quinaprilat (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaprilat (multiple doses every 6 hours on days 2 and 3)
Study: 2071560
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine administered four times daily for 3 weeks
Study: 20307823
Drug: Individualized yoga
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized yoga treatment
Study: 2475915
Drug: Laser +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser + high-dose-rate Iridium 192 afterloading therapy
Study: 1031798
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection tests (HOLLANDER criterion)
Study: 1031798
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection tests (BACHRACH criterion)
Study: 28727704
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with dexamethasone 8 mg
Study: 14509552
Drug: Non-antibiotic prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotic prescriptions (co-prescriptions)
Study: 14509552
Drug: Antibiotic prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescriptions
Study: 14509552
Drug: Mucomodifiers, steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucomodifiers, steroidal anti-inflammatory drugs, and bronchodilators
Study: 14509552
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs and antitussives
Study: 3544661
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine hippurate (MH) prophylaxis, 1 g three times daily
Study: 23989910
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection of flomoxef (group 1)
Study: 23989910
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of flomoxef (five additional doses after surgery, group 2)
Study: 21957982
Drug: Penile block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile block (0.25% bupivacaine, 0.5 mg·kg(‐1))
Study: 21957982
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural (0.25% bupivacaine, 0.5 ml·kg(‐1))
Study: 20049951
Drug: 6-Mercaptopurine (6-MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-Mercaptopurine (6-MP) at 30 mg/day for 12 weeks
Study: 20049951
Drug: 6-MP at
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-MP at 15-80 mg/day based on RBC 6-TGN, WBC count, and body weight
Study: 10195551
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg/kg as an i.v. bolus
Study: 10195551
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium 5 mg/kg as an i.v. bolus
Study: 8665995
Drug: Flosulide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosulide 25 mg b.d.
Study: 8665995
Drug: Flosulide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosulide (both doses)
Study: 8665995
Drug: Flosulide (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosulide (repeated treatment)
Study: 7437274
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine salicylate 1.8 g (corresponding to acetylsalicylic acid (ASA) 1.0 g)
Study: 7437277
Drug: Dipyrone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1.0 g
Study: 7437274
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine salicylate (ASA)
Study: 26626794
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (group B, n = 47)
Study: 24105610
Drug: Dronabinol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (2.5 mg twice daily for 4 weeks)
Study: 20577130
Drug: CPAP added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPAP added to conventional treatment (n = 38)
Study: 20577130
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (n = 37)
Study: 17434094
Drug: Glucose-potassium-insulin (GKI)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-potassium-insulin (GKI) infusions
Study: 8944090
Drug: Mipragoside 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipragoside 0.5% aqueous ophthalmic gel, administered four times a day for 2 weeks after a week of placebo treatment
Study: 8944090
Drug: Mipragoside 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipragoside 0.5% aqueous ophthalmic gel
Study: 24919195
Drug: Low-dose protocol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose protocol (100 kVp tube voltage, 100 mAs tube current, 3.2 pitch, sinogram affirmed iterative reconstruction)
Study: 23324248
Drug: DCE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCE plus best medical treatment (BMT)
Study: 19925464
Drug: Tacrolimus/MMF/steroids (Control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus/MMF/steroids (Control)
Study: 17884451
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/d for 12 weeks
Study: 10086835
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron mesylate intravenous infusion
Study: 10086835
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dolasetron mesylate intravenous infusion
Study: 10086835
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron mesylate intravenous infusion
Study: 10086835
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron mesylate oral administration
Study: 2188202
Drug: Whole-cell pertussis-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis-component diphtheria and tetanus toxoids and pertussis vaccine (DTP)
Study: 2188202
Drug: Licensed DTP
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed DTP vaccine
Study: 2188202
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis component DTP vaccine
Study: 2188202
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (in infants)
Study: 2188202
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (in 4- to 6-year-old children)
Study: 16135575
Drug: Intramuscular ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ephedrine 25 mg
Study: 7066739
Drug: Intramuscular ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ephedrine 50 mg
Study: 7066739
Drug: Intramuscular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular saline (placebo)
Study: 27235666
Drug: DHA supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplement >185 mg/day
Study: 27235666
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DHA supplement)
Study: 25820612
Drug: 3-month paliperidone
Normalized name: paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-month paliperidone palmitate (175, 263, 350, or 525 mg eq)
Study: 21063203
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (general)
Study: 17324670
Drug: Soy-protein-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-protein-rich diet (15 g soy protein/1,000 kcal daily)
Study: 15279619
Drug: B-group vitamin
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-group vitamin supplementation (5 mg of folate, 5 mg of vitamin B2, 50 mg of vitamin B6, 0.4 mg of vitamin B12) for 14 days
Study: 10939701
Drug: Intrathecal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal adenosine (500 microg in 1 ml volume)
Study: 10939701
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml saline)
Study: 1286502
Drug: Flumazenil (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.67 mg IV, range 0.2 to 1 mg)
Study: 25733342
Drug: Weekly fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly fruit consumption, past weight loss experience, and weight loss self-efficacy
Study: 19154823
Drug: 100 mouse
Normalized name: house mouse skin extract 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mouse units (MU)/mL dilution, 0.4cc/site, 4-quadrant injection
Study: 19154823
Drug: 100 MU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 MU/mL dilution, 0.4cc/site, 4 sites along endplate band
Study: 19154823
Drug: 20 MU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 MU/mL dilution, 2cc/site, 4-quadrant injection
Study: 11157183
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg QID for 10 days
Study: 9633738
Drug: Tramadol (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (210 mg/day)
Study: 25573751
Drug: Metformin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (dosage not specified)
Study: 25573751
Drug: Metformin pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin pharmacokinetics in GT genotype
Study: 25573751
Drug: Metformin pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin pharmacokinetics in GG genotype
Study: 19061721
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of autologous bone marrow mononuclear cells
Study: 8322572
Drug: Propofol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (all doses)
Study: 1443704
Drug: Propofol (larger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (larger doses)
Study: 31992758
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks
Study: 31992758
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in TG by 10 mg/dL from preconception to 28 weeks
Study: 31992758
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks (for BMI ≥25)
Study: 29454039
Drug: 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg selenium/d as selenium-enriched-yeast
Study: 29454039
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg selenium/d as selenium-enriched-yeast
Study: 29454039
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg selenium/d as selenium-enriched-yeast
Study: 23388205
Drug: Pre-biopsy educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-biopsy educational (ED) packet containing biopsy instruction sheet and a booklet about the biopsy procedure and prostate cancer treatment decision aid
Study: 19968611
Drug: Geranylgeranylacetone (GGA)
Normalized name: geranylgeranylacetone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geranylgeranylacetone (GGA) 150 mg/day
Study: 18334144
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule (3 capsules three times a day)
Study: 18334144
Drug: Deanxit (10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deanxit (10.5 mg twice daily)
Study: 18334144
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule plus Deanxit (both treatments)
Study: 18334144
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule
Study: 8473428
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (n = 10)